Vitamin D deficiency in newly diagnosed breast cancer patients

17 Background: Bone health is a particular concern for breast cancer survivors, because these women have 15% higher fracture risk than women without a history of breast cancer. Many studies have suggested that vitamin D deficiency may be involved in breast cancer initiation, progression, and prognosis. This study examines the prevalence of vitamin D deficiency among postmenopausal breast cancer patients in minority population. Methods: This retrospective study reviewed the electronic records of 200 postmenopausal breast cancer patients from ethnic groups of blacks, Hispanics and Asians. Results: Of the 200 patients, 84 (42%) had their 25-OHD levels checked at least once. Of patients, 42.7% found body mass index (BMI)>30kg/m2. There was significant difference between race and BMI (p<0.05). Black Vitamin D deficiency (level< 20ng/mL) found in 35 (41.7%), vitamin D insufficiency (level range 20-30ng/mL) found in 30 (35.7%) of the patients. The median serum 25-OHD level was 21 (range 4-65ng/ml). The serum 25-OHD levels did not have significant difference among blacks and Hispanics. Tumor stages found negatively correlated with 25-OHD levels r=-0.227 and p=0.04. Conclusions: This study revealed that vitamin D deficiency has a high prevalence among postmenopausal breast cancer minority population. Data from Third National Health and Nutrition Examination survey showed that mean serum 25-OHD levels among white, Hispanic and black women were 76ng/ml, 56.7ng/ml and 45.3ng/ml, respectively. Also, prevalence rate of vitamin D deficiency is reported in the studies among breast cancer patients are approximately 30%. Our data compared with this general population’s numbers is low; our median 25-OHD level was 21ng/ml. Our study found negative correlation with Vitamin D levels and stages of the breast cancer. Information is lacking on direct prognostic effect of vitamin D in breast cancer but this findings including our study support the hypothesis that vitamin D has a role in the pathogenesis of breast cancer. In the setting of breast cancer diagnosis either for bone health, or for breast cancer prognosis in postmenopausal women, we advocate routine 25-OHD levels screening for the vitamin D deficiency especially in minority populations would be beneficial.

Download Full-text

Is vitamin D deficiency in breast cancer patients associated with aggressive prognosis?

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e12511 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e12511-e12511

Author(s):

Omalkhair A. M. Abulkhair ◽

Ahmed Gasmelseed ◽

Ola Makram ◽

Ahmed Saadeddin ◽

Ahmed Hashim Mohamed

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Vitamin D Deficiency ◽

Cancer Patients ◽

Breast Cancer Patients

Download Full-text

Association of Serum Vitamin D Level and Vitamin D Receptor Expression among Newly Diagnosed Breast Cancer

Sains Malaysiana ◽

10.17576/jsm-2021-5011-16 ◽

2021 ◽

Vol 50 (11) ◽

pp. 3321-3332

Author(s):

Hani Ajrina Zulkeflee ◽

Tuan Salwani Tuan Ismail ◽

Tengku Ahmad Damitri Al-Astani Tengku Din ◽

Maya Mazuwin Yahya ◽

Wan Faiziah Wan Abdul Rahman

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Healthy Volunteers ◽

Cancer Patients ◽

Vitamin D Receptor ◽

Receptor Expression ◽

Cancer Tissue ◽

Newly Diagnosed ◽

Breast Cancer Patients ◽

Vitamin D Levels

There is a mushrooming interest in the anti-carcinogenic property of vitamin D. However, many researches reported a conflicting result in the association of vitamin D levels to certain types of cancer. This study was designed to assess the association between vitamin D and vitamin D receptor (VDR) expression with breast cancer. This case-control study, carried out at Hospital Universiti Sains Malaysia, Kelantan, involved 69 newly diagnosed breast cancer patients and 73 healthy volunteers. Serum 25(OH)D was taken and compared between 2 groups. VDR expression in patients’ breast tissue samples was determined by immunohistochemical staining method using anti-VDR antibody. 85.5% of breast cancer patients and 97.3% of healthy control were vitamin D insufficient with a mean (SD) of 13.36 (6.96) ng/mL and 13.05 (3.71) ng/mL, respectively, and the difference was not statistically significant. VDR expression showed cytoplasmic positivity in 75.4% of breast cancer tissue, followed by both cytoplasmic and nuclear positivity in 21.5% and complete absence in 3%. There was no significant association between VDR expression and hormone receptor status. In conclusion, there was a high prevalence of vitamin D deficiency among breast cancer and healthy volunteers in our study. There was no significant association between breast cancer and vitamin D. The VDR expression in breast cancer cells showed high cytoplasmic localization.

Download Full-text

Vitamin D Deficiency and Tumor Response Failure in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy at a Medical Center in Mexico

Clinical Oncology and Research ◽

10.31487/j.cor.2020.10.04 ◽

2021 ◽

pp. 1-4

Author(s):

Salvador Macias-Diaz ◽

Ana Lilia Castruita Avila ◽

Joaquin Gabriel Reinoso Toledo ◽

Mario Garcia Carrasco

Keyword(s):

Breast Cancer ◽

Vitamin D ◽

Neoadjuvant Chemotherapy ◽

Vitamin D Deficiency ◽

Cancer Patients ◽

Tumor Response ◽

Clinical Stage ◽

Molecular Profile ◽

P Value ◽

Breast Cancer Patients

Background: Vitamin D deficiency has been associated with not achieving a complete pathological response in patients with breast cancer after neoadjuvant chemotherapy. The objective of this study was to determine whether vitamin D deficiency is associated with tumor response failure in patients with breast cancer operated and who received neoadjuvant chemotherapy. Materials and Methods: This was a prospective, cross-sectional, analytical and observational study. Vitamin D was measured in patients with breast cancer who had received neoadjuvant chemotherapy and its association with tumor response was determined. For the inferential analysis, the Student’s t-test, chi-square test, and Fisher’s exact test were used. A p value <0.05 was considered statistically significant. Results: Thirty-six patients were included. There was tumor response failure to treatment in 69.3% and vitamin D deficiency occurred in 58.3%. No association was found between vitamin D deficiency and tumor response failure (p = 0.729), histological type (p = 0.691), molecular profile (p = 0.969), clinical stage (p = 0.468) or menopause status (p = 0.701). Conclusion: Vitamin D deficiency is not associated with tumor response failure in breast cancer patients who received neoadjuvant chemotherapy.

Download Full-text